Insilico’s Chemistry42 AI system integrated into UCB’s drug discovery programs
Insilico Medicine announces that UCB will integrate its AI-based system for de novo molecular design, Chemistry42™, into its drug discovery programsCredit: Insilico WHAT: Approximately two...